# Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

> **NCT04020575** · PHASE1 · RECRUITING · sponsor: **Minerva Biotechnologies Corporation** · enrollment: 69 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **BIOLOGICAL:** huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells
- **BIOLOGICAL:** huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D

## Key facts

- **NCT ID:** NCT04020575
- **Lead sponsor:** Minerva Biotechnologies Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-01-15
- **Primary completion:** 2025-01
- **Final completion:** 2035-01-15
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2023-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04020575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04020575, "Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04020575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*